TNGX - NASDAQ

Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGXยทNASDAQ

$22.04

+2.7%
HealthcareBiotechnology

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$2.56B
EPS-0.8700
P/E Ratio-25.34
Earnings Date08/04/2026
Tango Therapeutics, Inc.

Tango Therapeutics, Inc. Fair Value Envelope

TNGX ยท NASDAQ

Our analysis suggests that TNGX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $22.0416, this represents a potential HIDDEN relative to our calculated worth for Tango Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $22.0416

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$707.3M
+ Cash & Equivalents$112.3M
Firm Value-$595.0M
- Debt$33.6M
Equity Value-$628.6M
/ Shares Outstanding110,466,777B
DCF Value-$6
OVERVALUED BY 126%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$130.8M
-$123.2M
-$116.1M
-$109.3M
-$103.0M
-$97.0M
-$91.4M
-$86.1M
-$81.1M
-$76.4M
Maintenance CapEx
-$197.4K
-$186.0K
-$175.2K
-$165.0K
-$155.4K
-$146.4K
-$137.9K
-$129.9K
-$122.3K
-$115.2K
Owner Earnings
-$131.0M
-$123.4M
-$116.2M
-$109.5M
-$103.1M
-$97.2M
-$91.5M
-$86.2M
-$81.2M
-$76.5M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$121.3M
-$105.8M
-$92.3M
-$80.5M
-$70.2M
-$61.2M
-$53.4M
-$46.6M
-$40.6M
-$35.4M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TNGX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.